The Functional Topology of Phenylpiperazinium Agonists and Antagonists on the Nicotinic Acetylcholine Receptor Landscape: Pointing the Way for Future Therapeutic Management of Inflammation and Neuropathic Pain
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00216 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Hina Andleeb und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida 32610, United States. Hauptthemen laut MEDLINE: Nicotinic Agonists, Receptors, Nicotinic, Neuralgia, Piperazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Office of Advanced Cyberinfrastructure, National Institute of General Medical Sciences.
Abstract (Originalsprache)
The ganglionic blocker 1,1-dimethyl-4-phenylpiperazinium (diMPP) has agonist activity on a variety of neuronal nicotinic acetylcholine receptors (nAChRs). Recently, the related compound 1,1-diethyl-4-phenylpiperazinium (diEPP) has been used as a scaffold for the development of compounds with selectivity for homomeric α7 and α9 nAChRs, with the specific activity profiles depending on the side groups present on the phenyl group. We surveyed the activity of a family of phenylpiperazinium compounds with systematically designed differences in the base nitrogen and/or the phenyl side groups, on different nAChR subtypes. We evaluated activity on adult muscle type (α1β1εδ), ganglionic-like (α3β4), high affinity brain type (α4β2), and homomeric α7 and α9 nAChRs. In general, compounds with the dimethyl base group had the best activity for heteromeric receptors and homomeric α7 receptors. This activity could be tuned by the specific phenyl side groups. In contrast to the other subtypes studied, α9 receptors were better activated by analogs with larger alkyl groups on the base nitrogen, especially when the groups were asymmetrical on the base nitrogen, such that ethylmethyl-phenylpiperaziniums and propylmethyl-phenylpiperaziniums were more active on α9 than diethyl-phenylpiperaziniums. Our results may prove especially useful for the development of new drugs to treat inflammation and pain by targeting α9 nAChRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida 32610, United States.
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University, Indianapolis, Indiana 46208, United States.
ORCID-Profile: Hina Andleeb, Roger L Papke
Förderung
- NIGMS NIH HHS
- Office of Advanced Cyberinfrastructure
- National Institute of General Medical Sciences
Zitieren
APA
Andleeb, H., Gulsevin, A., & Papke, R. L. (2025). The Functional Topology of Phenylpiperazinium Agonists and Antagonists on the Nicotinic Acetylcholine Receptor Landscape: Pointing the Way for Future Therapeutic Management of Inflammation and Neuropathic Pain. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00216
Vancouver
Andleeb H, Gulsevin A, Papke RL. The Functional Topology of Phenylpiperazinium Agonists and Antagonists on the Nicotinic Acetylcholine Receptor Landscape: Pointing the Way for Future Therapeutic Management of Inflammation and Neuropathic Pain. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00216
BibTeX
@article{Andleeb2025,
author = {Andleeb, Hina and Gulsevin, Alican and Papke, Roger L},
title = {The Functional Topology of Phenylpiperazinium Agonists and Antagonists on the Nicotinic Acetylcholine Receptor Landscape: Pointing the Way for Future Therapeutic Management of Inflammation and Neuropathic Pain},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00216}
}
EUVIMED